Search company, investor...

DermTech International

Founded Year



Reverse Merger | IPO

Total Raised


Market Cap


Stock Price


About DermTech International

DermTech develops and commercializes qPCR assays for skin samples collected non-invasively using adhesive tape biopsy methods. The company's assays can analyze multiple gene targets to assess their level of RNA expression.

Headquarters Location

11099 N Torrey Pines Road Suite 100

La Jolla, California, 92037,

United States

(866) 450-4223

Missing: DermTech International's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: DermTech International's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing DermTech International

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

DermTech International is included in 6 Expert Collections, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Health Monitoring & Diagnostics

3,369 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data


Digital Health

13,118 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)



2,854 items

Companies developing, offering, or using electronic and telecommunication technologies to facilitate the delivery of health & wellness services from a distance. *Columns updated as regularly as possible; priority given to companies with the most and/or most recent funding.


Health IT

980 items

DermTech International Patents

DermTech International has filed 1 patent.

The 3 most popular patent topics include:

  • Rare diseases
  • Autoimmune diseases
  • Epidermal nevi, neoplasms, cysts
patents chart

Application Date

Grant Date


Related Topics





Application Date


Grant Date



Related Topics



Latest DermTech International News

In Brief This Week: 908 Devices, Natera, PerkinElmer, Hologic, Hamilton, BioFluidiX, More

Nov 18, 2022

Save for later NEW YORK –  Mass spectrometry firm 908 Devices reported this week that its Q3 2022 revenues were $15.8 million, up 26 percent from $12.5 million in Q3 of 2021. For the three months ended Sept. 30, the Boston-based company reported a net loss of $6.3 million, or $.20 per share, versus a net loss of $5.2 million, or $.19 per share, in the year ago period. The firm had $193.7 million in cash and cash equivalents at the end of the third quarter. It said it expects full-year 2022 revenues between $46 million and $49 million. Natera has laid off 58 employees from its California location. According to a company spokesperson, the layoffs were part of a regular business priority review and are not expected to have a large impact on the firm given the small percentage of its workforce affected. PerkinElmer said in a recent filing with the US Securities and Exchange Commission that it reduced its headcount by 40 employees during the third quarter and took $3.2 million in charges. The Waltham, Massachusetts-based firm said it cut its staff in the first three quarters of fiscal year 2022 to "realign resources to emphasize growth initiatives and integrate new acquisitions." The charges were comprised of $2.1 million associated with the firm's discovery and analytical solutions unit and $1.1 million associated with its diagnostics unit. Hologic said in a recent filing with the US Securities and Exchange Commission that it recorded $2.6 million in charges related to workforce reductions in fiscal year 2022 and $500,000 in charges related to facility closure costs. The firm did not disclose the effects on its headcount, which was 6,944 full-time employees as of Sept. 24. During the fiscal year, the company finalized a decision to close a Danbury, Connecticut facility for manufacturing breast health capital equipment products and allow most employees at that facility to transfer to positions at locations in Delaware and Massachusetts. Hologic also terminated employees across multiple divisions, outsourced one of its US distribution sites, and consolidated its offices in Germany during fiscal 2022. Hamilton Bonaduz said this week that it has acquired microdosing company BioFluidiX for an undisclosed amount. Freiburg, Germany-based BioFluidiX, which has around 20 employees, has developed patented processes that enable precise dispensing of liquid in the nanoliter and picoliter range. Hamilton, based in Switzerland, said it plans to retain the BioFluidiX brand and to expand the Freiburg location, moving it into the FRIZ Innovation Center near the University of Freiburg campus next year. Todos Medical said this week that its third quarter revenues rose 90 percent to $1.9 million from $1.0 million in Q3 of 2021. For the three months ended Sept. 30, the Tel Aviv, Israel-based diagnostics firm posted a net loss of $5.7 million, breaking even on a per-share basis, compared to a net loss of $10.4 million, or $.01 per share, a year ago. Todos attributed the decrease in its net loss to a $3.0 million reduction in financing expenses. It had cash and cash equivalents of $57,000 at the end of Q3. South Korean molecular diagnostics firm Seegene said this week that it has won a €45 million ($46.5 million) tender to supply diagnostic reagents to the regional government of Tuscany, Italy. Seegene's local subsidiary in Italy, Arrow Diagnostics, was selected as the supplier. Under the contract, Seegene will provide COVID-19 test kits as well as diagnostic reagents for the detection of human papillomavirus infections, sexually transmitted infections, antibiotic resistance determinants, and M. tuberculosis to 13 public hospitals in Tuscany starting in January of 2023. COVID-19 tests account for 57 percent and non-COVID products for 43 percent of the contract. Alphazyme, a Jupiter, Florida-based manufacturer of molecular biology enzymes, said this week that it has been awarded ISO 13485:2016 Quality Management Systems (QMS) certification by British Standards International (BSI). The firm, founded in 2018, provides a portfolio of enzymes used in molecular diagnostics and nucleic acid drug development. Quest Diagnostics said this week that its board of directors authorized a quarterly cash dividend of $.66 per share of common stock, payable on Feb. 1, 2023 to shareholders of record as of Jan. 18, 2023. Enalees, a French manufacturer of molecular diagnostic tests for the veterinary market, said this week that it has established a subsidiary in North Yorkshire, UK. Enalees, based in Evry, France, offers point-of-care animal diagnostic tests for canine, feline, and equine infectious diseases that use isothermal DNA amplification. Bio-Techne said this week that it has opened a new product innovation and manufacturing facility in Wallingford, Connecticut that will more than double the original site’s operational footprint. The site provides a fivefold increase in production capacity for the firm’s Ella immunoassay cartridges, to 500,000 per year. The site has increased laboratory, manufacturing, and cleanroom space, Bio-Techne said. Caris Life Sciences said this week that the University of Iowa Holden Comprehensive Care Center has joined the Caris Precision Oncology Alliance, a network of cancer centers that collaborate to advance precision oncology and biomarker-driven research. The alliance currently includes 74 cancer centers and academic institutions. DermTech and Sonora Quest Laboratories said this week that they have signed an agreement making Sonora Quest the exclusive laboratory in Arizona offering the DermTech Melanoma Test. According to the companies, the agreement will expand Arizona patients’ access to the test, which uses DermTech’s Smart Sticker technology to collect skin cells to be tested for melanoma-associated genomic markers. Agilent Technologies said this week that its board of directors has declared a quarterly dividend of $.23 per share of its common stock, payable on Jan. 25 to all shareholders of record on Jan. 3. Mainz Biomed said this week that it has initiated eAArly DETECT, a US extension of its European feasibility study, ColoFuture, to evaluate the integration of five novel mRNA biomarkers into its ColoAlert colorectal cancer detection test. The company licensed the biomarkers earlier this year from the Université de Sherbrooke in Quebec, Canada. Both ColoFuture and eAArly DETECT are multi-center studies assessing the potential of these biomarkers to identify advanced adenomas, a type of precancerous polyp associated with CRC. Mainz Biomed plans to complete enrollment for eAArly DETECT in Q1 of 2023 and to report topline results in the first half of the year. Based on the outcome, it may include any of the biomarkers in its US pivotal study, scheduled to start in Q4 of 2022. ERS Genomics said this week that it has signed on Atlatl Innovation Center as its non-inclusive agent for licensing its intellectual property for commercial or research use in China. ERS handles foundational CRISPR/Cas9 IP held by Emmanuelle Charpentier that includes 89 patents in more than 80 countries. Atlatl is an R&D center with locations at multiple science parks in China. Pathnostics said this week that it has opened a new lab in Lake Mary, Florida, and is expanding its lab and headquarters in Irvine, California. The Florida lab will initially focus on the firm's Guidance UTI test for the rapid identification and treatment of complicated, recurrent, and persistent urinary tract infections. The assay combines PCR and pooled antibiotic susceptibility testing. The lab is an 8,500 square foot facility and will have 30 employees to start. The new California facility will have 55,000 square feet, and relocation to the site is expected to be completed by the end of the year. Pathnostics also maintains a third, CAP-accredited and CLIA-certified lab in Royal Oak, Michigan. Streamline Scientific of Birmingham, Alabama, said this week that it has partnered with UroGPO to support urologists and their in-house PCR testing labs. UroGPO is a group purchasing organization that provides services to urology professionals. Streamline offers consultation services for physician practices and reference labs for implementing in-house PCR labs. It also runs its own CLIA-certified reference lab in Alabama. Seoul National University Bundang Hospital Biomedical Research Institute said this week that it has signed a memorandum of understanding with bioinformatics company Cipherome to standardize clinico-genomics research at its Precision Medicine Center using Cipherome's precision medicine research platform. Cipherome offers the Xentinel Compass Platform to analyze large-scale genomic and clinical data in a fast and easy manner. In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on GenomeWeb.

DermTech International Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

DermTech International Rank

DermTech International Frequently Asked Questions (FAQ)

  • When was DermTech International founded?

    DermTech International was founded in 1996.

  • Where is DermTech International's headquarters?

    DermTech International's headquarters is located at 11099 N Torrey Pines Road, La Jolla.

  • What is DermTech International's latest funding round?

    DermTech International's latest funding round is Reverse Merger.

  • How much did DermTech International raise?

    DermTech International raised a total of $33.51M.

  • Who are the investors of DermTech International?

    Investors of DermTech International include Constellation Alpha Capital, Gary Jacobs, Gene Salkind, Western States Investment Group and Annex Ventures.

  • Who are DermTech International's competitors?

    Competitors of DermTech International include La Jolla Pharmaceutical Company, DermaSensor, Fujirebio, Molmed, Altimmune and 14 more.

Compare DermTech International to Competitors

Origin BioMed

Origin BioMed Inc., is an innovative biotechnology company currently expanding the markets for its exclusive pain relief,diabetic, skin and lip care products.

Efficas Logo

Efficas is a biotechnology company focused on the discovery and rapid development of nutritional bioactives with clinically-proven efficacy for the management of human and animal health. Efficas' lead product will be a product derived from an edible fruit to assist in the control of atopic dermatitis.

Sunzen Biotech

Sunzen Biotech Berhad ("Sunzen Biotech"‚) is an animal health specialist, focused on developing, manufacturing and marketing animal health care products. The company market a range of animal health products which includes feed additives, nutritional feed supplements, veterinary pharmaceuticals, animal vaccines and other animal health care products for livestock such as poultry, swine, goats and cattle, as well as companion animals. The company develop and manufacture non-antibiotic animal health products that comply with international safety standards to ensure public safety. And in recognition of the company's focused Research and Development in non-antibiotic animal biotechnology, Sunzen Biotech has been accorded BioNexus Status, which entitles Sunzen to tax incentives and other privileges specified under the Bionexus bill of guarantees, from the Malaysian Biotechnology Corporation. Sunzen is also the sole distributor for Pfizer Animal Health products in Malaysia, Singapore, andnBrunei. The company are proud to say that today "Sunzen"‚ products are supplied to feed millers and livestock producers in Malaysia and across the region.


InsectiGen, Inc. is a biotechnology company focused on discovery and development of biopesticides. Founded by Clifton Baile, PhD and Michael Adang PhD, InsectiGen has licensed IP from the University of Georgia associated with modified proteins form the intestine of insects that enhance natural insecticides produced by Bacillus thuringensis (Bt).


Vybion is a developer and manufacturer of recombinant proteins for therapeutic and diagnostic applications. It uses its technologies along with a highly skilled staff to develop therapeutics, vaccines, diagnostics and bioavailability for pharmaceutical and biotechnology companies.


Fujirebio, fka Innogenetics, conceives, develops, produces and markets in vitro diagnostics (IVD) testing solutions.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.